share_log

Key Takeaways From ADMA Biologics Analyst Ratings

Benzinga ·  Oct 14, 2024 20:01  · Ratings

Throughout the last three months, 4 analysts have evaluated ADMA Biologics (NASDAQ:ADMA), offering a diverse set of opinions from bullish to bearish.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings22000
Last 30D10000
1M Ago01000
2M Ago00000
3M Ago11000

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $19.0, a high estimate of $20.00, and a low estimate of $18.00. Witnessing a positive shift, the current average has risen by 20.63% from the previous average price target of $15.75.

1728907258_0.png

Analyzing Analyst Ratings: A Detailed Breakdown

The perception of...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment